C olorectal cancer disseminates by 3 different routes: hematogenous metastasis, lymphatic metastasis, and direct implants on peritoneal surfaces. In a substantial number of patients, disease progression that is isolated to the resection site or to the peritoneal surfaces may occur. Disease progression will eventually compromise gastrointestinal function and cause bowel obstruction. It is possible that elimination of locoregional disease will have an impact on the survival of these cancer patients, in whom a prominent cause of death is peritoneal carcinomatosis. 1 Traditionally, there was a mutual agreement in the oncology community that those patients with colorectal peritoneal carcinomatosis (CRPC) were incurable. Neither systemic chemotherapy nor intraperitoneal chemotherapy alone demonstrated any significant impact on survival.
Recently, there has been an upsurge of interest in reexamining the management of peritoneal surface malignancy, utilizing cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC). [2] [3] [4] [5] [6] [7] [8] [9] This combined surgical and chemotherapeutic cytoreductive approach has demonstrated some promising results in patients with peritoneal carcinomatosis from colorectal origins. 10 With better insight into the natural history of these diseases and as more evidence that supports the comprehensive management becomes available, it is expected that there will be a shift in the general concept of treatment approach for peritoneal carcinomatosis. The time needed for such a change may be difficult to predict. However, what can be said with certainty is that the current state-of-the-art for treatment of colorectal peritoneal carcinomatosis involves a multidisciplinary team approach. 11 Since the initiation of the peritoneal surface malignancy program at the St. George Hospital in Sydney, 50 patients with isolated CRPC were uniformly treated with the combined treatment modality. Based on this prospectively collected database, we conducted a detailed analysis to evaluate the survival outcome of CRPC and to elucidate the influence of potential prognostic factors on survival after the combined treatment.
METHODS
Between January 1997 and October 2007, a total of 50 patients underwent CRS combined with PIC for peritoneal carcinomatosis from colorectal origin (nonappendiceal), lead by a single surgeon (D.L.M.) at the St. George Hospital in Sydney. Signed informed consent was obtained from all patients. All patients were followed prospectively and no patients were lost to follow-up.
Selection Criteria
The current study included patients who were Ͼ18 and Յ80 years old, with good performance status (World Health Organization Performance Status Յ2) and had intraoperative findings as localized or generalized peritoneal carcinomatosis. All patients were managed by a standardized treatment protocol, including CRS and PIC. The exclusion criteria consisted of bleeding diatheses not responding to medical treatments (international normalized ratio prothrombin time Ͼ1.5 and platelet counts Ͻ100 ϫ 10
9
) and extra-abdominal metastasis. The consensus on the suitability of CRS and PIC for each patient was obtained with a multidisciplinary team approach at weekly meetings by a group of surgeons, medical oncologists, and radiologists.
All patients underwent extensive preoperative investigations, which included physical examination, abdominal, pelvic and chest computed tomography (CT) scans to assess the extent of the disease involved. CT scans were performed following the administration of oral and intravenous contrast media. Positron emission tomography (PET) was routinely performed in these patients. Extent of prior surgery was determined according the number of abdominopelvic regions dissected during previous surgery.
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Cytoreductive Surgery
The volume and extent of the tumor deposits were prospectively recorded using the peritoneal cancer index (PCI), as described by Jacquet and Sugarbaker. 12 It is an assessment combining lesion size (lesion size 0 to 3) with tumor distribution (abdominopelvic region 0 to 12), to quantify the extent of disease as a numerical score (PCI 0 -39). 12 All patients underwent CRS by the same surgical team with intent to remove all visible intraperitoneal tumor deposits. CRS was performed according to Sugarbaker's techniques. 13 In short, peritonectomy procedures include total anterior parietal peritonectomy, omentectomy Ϯ splenectomy, right and left subphrenic peritonectomy, pelvic peritonectomy, and lesser omentectomy Ϯ cholecystectomy. 13 These resections were used at the anatomic sites where there was visible evidence of disease. All sites and volumes of the residual disease following the cytoreductive surgery were also prospectively recorded using the completeness of cytoreduction (CC) score. 12 A CC-0 indicated no visible evidence of disease. CC-1 indicated residual tumors Յ2.5 mm in diameter. CC-2 indicated residual tumors between 2.5 mm and 2.5 cm in diameter. CC-3 indicated residual tumors Ͼ2.5 cm in diameter or a confluence of tumor nodules present at any site.
Perioperative Intraperitoneal Chemotherapy
After the cytoreduction was completed but before intestinal anastomosis or repair of seromuscular tears, the abdomen and pelvis was instilled with hyperthermic intraperitoneal chemotherapy (HIPEC, 10 to 12.5 mg/m 2 mitomycin C) in the operating room at approximately 42°C in 3 L of 1.5% dextrose peritoneal dialysis solution for 90 minutes. The coliseum technique was used. The intraperitoneal chemotherapy solution was manually distributed to facilitate maximal contact and penetration of the chemotherapy into residual cancer cells.
Early postoperative intraperitoneal chemotherapy (EPIC, 650 to 800 mg/m 2 5-fluorouracil per day) was given in 1 L of 1.5% dextrose peritoneal dialysis solution from postoperative day 1 to day 5. This was given either in the intensive care unit (ICU) or high dependency unit (HDU). The intraperitoneal chemotherapy was allowed to dwell for 23 hours and was then removed by closed suction drains over the course of 1 hour. When the abdomen was cleared of fluid as completely as possible, the next instillation was commenced. In the present clinical pathway, all patients were to receive EPIC. However, in patients with hemodynamic instability or those experiencing early postoperative complications, EPIC was withheld. The criteria for proceeding with EPIC included absence of leakage of intraperitoneal chemotherapy system; absence of major organ failure; and ability to tolerate increased intra-abdominal fluid volume and intra-abdominal pressure with adequate urine output. EPIC was given only with the consensus of surgical, medical, and ICU teams.
Study Methods
All patients were then followed prospectively at monthly intervals for the first 3 months and 6 monthly intervals thereafter until the last time of contact or death. The follow-up review included clinical examination, measurement of relevant tumor markers, and assessment of abdominopelvic CT scans. All the clinical and treatment-related data were prospectively collected and entered into a computerized database. Perioperative morbidity data were graded according to the severity of the complications. Mild complications required medical or no treatment for resolution. Moderate complications required interventional procedures for resolution, such as a CT-or ultrasound-guided percutaneous drainage. Severe complications required returning to the operating room or intensive care support. Hospital mortality was defined as any death that occurred during the same hospital admission for CRS. Outcomes were reported on an intentionto-treat basis. All patients who underwent the combined procedure were discharged from the hospital at the time that this report was written.
Survival analysis was performed by using KaplanMeier method and compared using the log-rank test. For multivariate analysis, a Cox-regression (Cox proportional hazards model) with forward stepwise selection of covariates and with entering and removing limits of P Ͻ 0.10 and P Ͼ 0.05 was used. All statistical analyses were performed using the Statistical Package for Social Sciences for Windows (Version 14.5; SPSS GmbH, Munich Germany). A significant difference was defined as P Ͻ 0.05.
RESULTS
Descriptive Data
Between January 1997 to October 2007, a total of 50 patients who were judged preoperatively to be candidates for the combined treatment were included in the statistical analysis. Seven patients (14%) found to have unexpected extensive disease during intra-abdominal exploration underwent palliative bypass procedures, and 2 patients (4%) were hemodynamically unstable during the operation. In these pa-tients, HIPEC was not given. The numbers of patients treated during the study period by every 2-year interval were 4, 1, 7, 17, and 21, which might reflect the fact that there was an increase in the awareness of the combined treatment option for isolated CRPC. The mean age at the time of CRS was 55 (SD ϭ 14) years. There were 19 (38%) male patients. International Union Against Cancer TNM staging of the primary tumor was stage II in 13 patients (26%), stage III in 16 patients (32%), and stage IV in 21 patients (42%). Three patients had well-differentiated; 34 patients had moderately differentiated and 13 patients had poorly differentiated tumors. The mean PCI was 12 (SD ϭ 8). Forty-one patients (82%) had CC-0 cytoreduction. Three patients (6%) had CC-1; 4 patients (8%) had CC-2, and 2 patients (4%) had CC-3 cytoreduction. There was no hospital mortality. The operative duration was 7 (SD ϭ 0.5) hours. The mean ICU, HDU, and total hospital stay was 4 (SD ϭ 7), 5 (SD ϭ 7), and 29 (SD ϭ 31) days, respectively.
The mean unit of blood transfusion was 4 (SD ϭ 4). Twelve patients (24%) had no complications. The remaining patients experienced one or more complications. Twentythree patients (46%) sustained 33 mild adverse events, which required medical or no treatment for resolution. In the descending order of frequency, these mild adverse events included pleural effusion (n ϭ 14), febrile episodes (n ϭ 7), small bowel obstruction (n ϭ 5), fistula (n ϭ 2), cardiac arrhythmia (n ϭ 2), pneumonia (n ϭ 1), chemotherapyrelated renal impairment (n ϭ 1), and pulmonary embolism (n ϭ 1). Six patients (12%) sustained 14 moderate adverse events, which required invasive medical intervention for resolution. These moderate adverse events included febrile episodes caused by intra-abdominal abscess (n ϭ 5); fistula (n ϭ 3); pancreatic leak (n ϭ1) requiring a CT-guided percutaneous drainage; symptomatic pleural effusion requiring insertion of chest drain (n ϭ 3); and chemotherapy leak (n ϭ 2). Nine patients (18%) had 10 severe adverse events, which required returning to the operating room or intensive care support; in the descending order of frequency they included: line-related septicemia (n ϭ 3); pneumonia causing respiratory distress, requiring endotracheal intubation (n ϭ 2); perforation of viscus (n ϭ 2); small bowel obstruction (n ϭ 1); cardiac arrhythmia (n ϭ 1); and disseminated intravascular coagulopathy (n ϭ 1).
Survival Data
Follow-up of these 50 patients was complete, with a median follow-up of 14 months (range 1-56). The median survival was 29 months (range 1-56), with 1-, 2-and 3-year survival of 79%, 67%, and 39%, respectively (Fig. 1) . Thirtythree patients (66%) remained alive at the last time of follow-up.
Univariate Analysis of Potential Prognostic Factors for Survival
Eight clinicopathologic and 7 treatment-related factors were analyzed for their prognostic significance in these 50 patients. Table 1 demonstrates univariate analysis of 8 clin- 
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Colorectal Peritoneal Carcinomatosis icopathologic factors for overall survival. Three clinicopathologic factors were found to be significant for overall survival: tumor differentiation (P Ͻ 0.001) (Fig. 2) , peritoneal cancer index (P ϭ 0.021) (Fig. 3) , and completeness of cytoreduction (P Ͻ 0.001) (Fig. 4) . Age at the time of surgery (P ϭ 0.436), gender (P ϭ 0.228), TNM staging (P ϭ 0.945), and extent of prior surgery (P ϭ 0.153) and HIPEC (P ϭ 0.953) were not significant prognostic indicators for overall survival. Univariate analysis of 7 treatment-related factors for overall survival was also performed. All treatment-related factors, including moderate morbidity (P ϭ 0.916), severe morbidity (P ϭ 0.352), transfusion requirement (P ϭ 0.168), duration of operation (P ϭ 0.073), duration of ICU stay (P ϭ 0.603), HDU stay (P ϭ 0.361), and overall hospital stay (P ϭ 0.938) were not significant prognostic indicators for overall survival.
Multivariate Analysis for Survival
In the multivariate analysis of overall survival, 2 factors were identified to be independently associated with an improved survival: well/moderately differentiated tumor (hazard ratio ϭ 4.011; 95% confidence interval ϭ 1.024 to 8.826; P ϭ 0.045) and complete cytoreduction (hazard ratio ϭ 5.152; 95% confidence interval ϭ 1.185 to 10.179; P ϭ 0.023).
DISCUSSION
At our center the combined procedure is indicated for patients with isolated CRPC. In this study, the overall median survival was 29 months and 3-year survival rate was 39%. These survival results for what was regarded as incurable disease are very encouraging. From a surgeon's standpoint, we believe that the emphasis should be placed on stringent patient selection to identify most appropriate surgical candidates to avoid futile aggressive treatments. All of our patients were selected preoperatively by chest, abdominal, and pelvic CT scans, and potential extra-abdominal metastasis was ruled out by PET. In view of a positive result from the only randomized controlled trial 2 and in absence of any proven evidence so far on the efficacy of systemic chemotherapy for this selected group of patients, refusing patients with isolated CRPC to undergo a potentially curative procedure may seem controversial. Indeed, the current opinions on the standard of care for patients with CRPC are polarized. Many medical and surgical oncologists are still insisting on more proof before 
Yan and Morris
accepting the combined approach. In contrast, others, including most specialist peritonectomy surgeons, would believe that it is inappropriate to conduct further randomized trials, including a no cytoreduction group, when there is no reported evidence demonstrating the efficacy of modern systemic chemotherapy in this group of patients. 10 As outlined in this report, not all patients are suited for the combined procedure. Patients must be fit for surgery and have to undergo extensive preoperative work-up to determine the extent of peritoneal disease and exclude any extra-abdominal metastasis by best possible means, similar to liver resection, which is best indicated for those with resectable locoregional disease. In this study, 3 clinicopathologic factors were found to be significant for overall survival: tumor differentiation, peritoneal cancer index and completeness of cytoreduction. In a careful review of the literature 4 other studies also demonstrated that tumor differentiation has a significant impact on overall survival. 3, 6, 9, 14 Various prognostic variables for survival have been reported. Among these, PCI deserves special attention because it quantifies the tumor burden and uniformly correlates with survival. 1, 3, [15] [16] [17] [18] [19] [20] [21] [22] However, currently the cut-off of a low PCI associated with a favorable survival has not been clearly defined, in that the available clinical evidence does not allow reliable prediction on when it is suitable to proceed with the combined treatment solely based on the value of PCI. Sugarbaker reported that the median survival for PCI Ͻ20 was 41 months, compared with 16 months for PCI Ͼ20. 4 Elias and colleagues found that the survival difference was between PCI Յ15 and PCI Ͼ15. At the Milan Peritoneal Oncology Consensus Meeting, 67% of the voters did not regard a PCI Ͼ20 as an absolute exclusion criterion for the combined treatment. The present study demonstrated encouraging results for PCI Ͻ10, with a 3-year survival of 77%.
Sugarbaker proposed the CC-score, which quantifies the extent of residual disease into 4 categories. 12 Nearly all treatment centers agree that in both noninvasive and invasive peritoneal disease, the CC-score is the principle prognostic indicator for survival (Table 2) . 1-3,5,6,8,14 -17,19 -28 In CRPC, complete cytoreduction may require a CC-0 score. 1-3,5,6,8,14 -17,19 -28 In the Dutch randomized trial, 17 of the 18 patients who had CC-0 cytoreduction were still alive at the completion of the study. 2 In 1996, Elias and coworkers attempted a randomized study comparing CRS and EPIC versus CRS without EPIC. 29 The trial was terminated prematurely due to recruitment difficulties. Although EPIC did not have any measurable effect, both arms demonstrated a 2-year survival of 60% in patients who had CC-0 cytoreduction. The authors concluded that CC-0 was a prerequisite for long-term survival. 29 A recent update from the same group reported a 5-year survival of 49% in 30 patients who received CC-0 cytoreduction and heated intraoperative oxaliplatin. 7 In the registry study by These results were significantly better than CC-1 or CC-2. To date one RCT by the Dutch group has demonstrated superior survival of the combined approach over the traditional 5-fluorouracil-based systemic chemotherapy for CRPC. 2 Controversies still exist on whether conducting more randomized controlled trials is necessary. Given the promising results of the combined approach reported today and the lack of evidence on the efficacy of systemic chemotherapy for patients with isolated CRPC, one has to appreciate the great degree of difficulty of recruiting patients to conduct such trials. 10 Furthermore, there is not sufficient equipoise among most peritonectomy surgeons to permit randomization. However, this does not deny the need of further clinical evidence. Individual centers should maintain their prospective collected database on an intention-to-treat basis and may consider participating in multi-institutional registry studies, so that the data and the experience offered by one center can be shared by others. 30 In conclusion, the present study showed that patients with low tumor volume, well/moderately differentiated tumors and complete cytoreduction are likely to have an improved survival after CRS and PIC. We have emphasized that patients with good performance status and isolated CRPC should be considered for the combined treatment, before embarking on palliative systemic chemotherapy alone. In other words, in view of a positive RCT and numerous phase II studies, the current state-of-the-art for treatment of isolated CRPC should involve cytoreductive surgery and perioperative intraperitoneal chemotherapy, unless further studies on systemic chemotherapy or other alternative treatments demonstrate superior results in this selected group of patients.
